Spero Therapeutics (SPRO) Common Equity (2016 - 2025)
Historic Common Equity for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to $26.5 million.
- Spero Therapeutics' Common Equity fell 5955.55% to $26.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.5 million, marking a year-over-year decrease of 5955.55%. This contributed to the annual value of $46.1 million for FY2024, which is 5685.16% down from last year.
- Spero Therapeutics' Common Equity amounted to $26.5 million in Q3 2025, which was down 5955.55% from $32.8 million recorded in Q2 2025.
- Spero Therapeutics' Common Equity's 5-year high stood at $118.8 million during Q1 2021, with a 5-year trough of $26.5 million in Q3 2025.
- In the last 5 years, Spero Therapeutics' Common Equity had a median value of $64.8 million in 2023 and averaged $67.3 million.
- Its Common Equity has fluctuated over the past 5 years, first plummeted by 7096.92% in 2022, then soared by 6532.75% in 2023.
- Quarter analysis of 5 years shows Spero Therapeutics' Common Equity stood at $88.3 million in 2021, then fell by 13.99% to $75.9 million in 2022, then soared by 40.77% to $106.9 million in 2023, then plummeted by 56.85% to $46.1 million in 2024, then plummeted by 42.56% to $26.5 million in 2025.
- Its Common Equity was $26.5 million in Q3 2025, compared to $32.8 million in Q2 2025 and $33.8 million in Q1 2025.